News | January 15, 2026
BioNTech maps pivotal oncology milestones for 2026
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Elanco expects Befrena to launch in the US in the first half of 2026
Subscribe To Our Newsletter & Stay Updated
